IPO Trending
MOLBIOEQ / NSE, BSEAllotted

Molbio Diagnostics Limited

Founded in 2000, Molbio Diagnostics Limited is a healthcare company focused on providing fast, accurate, and affordable diagnostic solutions for both infectious and non-communicable diseases. Its key product, the Truenat platform, is a portable PCR-based testing system that can deliver results within an hour, even in remote or low-resource areas, and is used to detect diseases like tuberculosis, COVID-19, hepatitis, HIV, and HPV. The company also offers radiology, digital pathology, and breast health screening solutions through its group entities and partners. It operates five manufacturing facilities across India to produce diagnostic devices, test kits, and portable X-ray systems. With a presence in over 80 countries and a strong distributor network, Molbio serves public health programs, hospitals, and diagnostic labs worldwide, generating revenue from both device sales and recurring test kit usage. As of March 31, 2025, the company had around 1,000 permanent employees along with over 1,500 contract workers.

₹768 - ₹807GMP ₹12670.26x sub
GMP+₹126
Est. Listing Price₹933
Review-Analyst Consensus Verdict

Not Rated

Axis Capital Limited recommendation is Not Rated.

Apply
964%
May Apply
17%
Neutral
17%
Avoid
00%
Not Rated
321%
Brokers / Analysts Review
ReviewerRecommendationReport
Axis Capital LimitedNot RatedDownload
Swastika Investmart LimitedApplyDownload
Ajcon Global Services LimitedApplyDownload
Anand Rathi Share & Stock Brokers LimitedApplyDownload
Bajaj Financial Securities LimitedNot RatedDownload
Beacon Capital Advisors Private LimitedApplyDownload
BP Equities Private LimitedApplyDownload
Canara Bank Securities LimitedApplyDownload
Capital MarketMay ApplyDownload
DRChoksey FinServ Private LimitedApplyDownload
GEPL Capital Private LimitedApplyDownload
HDFC Securities LimitedNot RatedDownload
SMC Global Securities LimitedNeutralDownload
Sushil Financial Services Private LimitedApplyDownload

Molbio Diagnostics Limited IPO Review & Research Verdict (2026)

Financial review and research analysis for Molbio Diagnostics Limited (MOLBIO) IPO. Evaluate company business model strengths, competitive positioning, historical revenue growth, and valuation metrics.

Analyst VerdictNot RatedBroker Consensus
Company P/EFair ValuePrice to Earnings
Industry P/EPeer BenchmarkListed Competitors
Overall Rating4 / 5Fundamental Score

Explore More About Molbio Diagnostics Limited IPO

Frequently Asked Questions (FAQs) - Molbio Diagnostics Limited Reviews

Molbio Diagnostics Limited IPO Review (2026): Apply or Avoid? Financials & Valuation | IPO Trending